Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UMD, GBSI Partner to Advance Antibody Standards

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Collaboration will allow for assessment of the current antibody standards landscape and identify and characterize the need for additional standards.

The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards.

To help enable this work, the Fischell Department of Bioengineering has named Dr. Simran Kaur the recipient of this year’s GBSI-funded Postdoctoral Research Fellowship, effective June 30, 2014. As the GBSI Fellow, Kaur will be an integral part of the M-CERSI community, interacting frequently with faculty and students, Fischell Department of Bioengineering Chair William Bentley, UMD Director of Regulatory Science Innovation Initiative Lex Schultheis, the Food and Drug Administration (FDA), the National Institute of Standards and Technology (NIST), and industrial consortia members including GBSI and its Antibodies Task Force.

Kaur received her Ph.D. in Microbiology from the Department of Microbial Pathogenesis, Helmholtz Centre for Infection Research in Braunschweig, Germany in 2009, and both her M.S. (2005) and B.S. (2002) in Biophysics from Panjab University in Chandigarh, India. Prior to her appointment as the GBSI Fellow, Kaur was a postdoctoral fellow at the University of Maryland, Baltimore, and a volunteer research associate at the Department of Chemical and Biomolecular Engineering at Johns Hopkins University. Her recent research focus areas include molecular biology, protein chemistry and cell biology.

As the GBSI Fellow, Kaur will design and implement a research program on how the application of standards can advance the quality, efficacy and reproducibility of antibodies in research and development, with a major publication as the intended result.

“Dr. Kaur will develop a new scientific tool for FDA regulation of therapeutic monoclonal antibodies known as ‘biosimilars,’” Schultheis said. “Biosimilar antibodies are intended to be therapeutically equivalent to the innovator antibody, just as generic drugs may be substituted for a small molecule drug whose patent has expired.  Dr. Kaur's work will help inform FDA and the biologic pharmaceutical industry how to develop industry-wide standards to improve patient access to the highest quality medicine, especially in treatment of cancer and arthritis.”

“We are pleased to partner with University of Maryland through the creation and funding of the GBSI Fellowship, and participation on M-CERSI’s consortium for 2014,” said Dr. Leonard Freedman, President of GBSI. “Our collaboration contributes to reaching GBSI’s goal to ensure that best practices and standards in antibodies are adopted and widely implemented in the scientific community.”  GBSI’s other initiatives include:  developing educational curricula in quality research design for graduate students and post-docs, advancing best practices and standards in cancer cell authentication, establishing a registry of sample procurement standard operating procedures, and producing an analysis and publication on the economic impact of irreproducibility in biomedical research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!